Patel Gautam 4

What Happened
Patel Gautam, a director of Amneal Pharmaceuticals (AMRX), had a conversion/exercise of derivative awards and a reported grant. On May 7, 2026 the filing shows conversion/exercise of 34,819 derivative units into shares (acquired) and a simultaneous disposition of 34,819 shares at $0.00 (no cash proceeds reported). The filing also reports a grant/acquisition of 19,824 restricted stock units (RSUs) on May 6, 2026 at $0.00 (derivative).

Key Details

• Transaction dates: Grant reported 2026-05-06; conversion/exercise and disposition reported 2026-05-07. Form 4 filed 2026-05-08.
• Prices/values reported: All entries show $0.00 or N/A for per-share price and $0 total proceeds for the 34,819-share disposition.
• Shares owned after transaction: Not specified in the filing.
• Notable footnotes from the filing:
  • F1: Each RSU represents a contingent right to one share of Class A common stock.
  • F2: The 34,819 RSUs were granted on May 6, 2025 and vest on May 7, 2026.
  • F3: RSUs vest on the later of the issuer's first annual meeting after the grant or one year after grant.
• Filing timeliness: Filed May 8, 2026; transactions occurred May 6–7, 2026 — the Form 4 was submitted within the typical 2-business-day reporting window.

Context
These entries involve RSUs/derivative activity (vesting/conversion and a new RSU grant), not an open-market purchase or a cash sale. The reported disposition of 34,819 shares at $0.00 does not show cash proceeds and the filing does not state the reason (e.g., tax withholding, share surrender, or internal transfer). For retail investors, grants and vesting are typically administrative and do not necessarily indicate buying or selling intent in the market.